CURRICULUM VITAE Sonia Isabella Skarlatos National Institutes of ...

CURRICULUM VITAESonia Isabella SkarlatosNational Institutes of HealthNational Heart, Lung and Blood InstituteTwo Rockledge Center, Suite 81246701 Rockledge Drive, MSC 7940Bethesda, MD 20892-7940(Work) 301-435-0556January 15, 2013Personal DataBirth Place:Citizenship:La Rochelle, FranceU.S. CitizenProfessional Positions2009-presentDeputy Director, Division of Cardiovascular Sciences, National Heart,Lung and Blood Institute, National Institutes of Health, Bethesda, MD2006-2009 Acting Director, Division of Cardiovascular Diseases, National Heart, Lungand Blood Institute, National Institutes of Health, Bethesda, MD2004-present2000-presentDeputy Director, Division of Cardiovascular Diseases, National Heart,Lung and Blood Institute, National Institutes of Health, Bethesda, MDNHLBI Gene Therapy Coordinator, National Heart, Lung and BloodInstitute, National Institutes of Health, Bethesda, MD2000-2004 Director, Vascular Biology Research Program, Division of Heart andVascular Diseases, National Heart, Lung and Blood Institute, NationalInstitutes of Health, Bethesda, MD1995-2000 Scientific Research Group Leader, Molecular Genetics and MedicineScientific Research Group, Vascular Biology Program, Division of Heartand Vascular Diseases, National Heart, Lung and Blood Institute, NationalInstitutes of Health, Bethesda, MD1992-1995 Health Scientist Administrator, Atherosclerosis Scientific Research Group,Vascular Biology Program, Division of Heart and Vascular Diseases,National Heart, Lung and Blood Institute, National Institutes of Health,Bethesda, MD1988-1992 Senior Staff Fellow, Section of Experimental Atherosclerosis,National Heart, Lung and Blood Institute, National Institutes of Health,1

Bethesda, MD1985-1988 Staff Fellow, Section of Experimental Atherosclerosis,National Heart, Lung and Blood Institute, National Institutes of Health,Bethesda, MD1982-1985 Research Assistant, Department of Physiology, Pennsylvania StateUniversity, University Park, PA1981-1982 Teaching Assistant, Department of Biology, ShippensburgUniversity, Shippensburg, PASummer 1980Research Technician, Department of Cardiology, Hershey MedicalCenter, Hershey, PAEducation1982-1985 Doctorate of Philosophy: PhysiologyPennsylvania State University, University Park, PA1981-1982 Master of Science: BiologyShippensburg University, Shippensburg, PA1976-1981 Bachelor of Science: Biology(Part-time)Shippensburg University, Shippensburg, PA1973-1974 University of Maryland, European Extension,Athens, GreeceFall 1971University of Pittsburgh, Johnstown, PA1967-1971 High School DegreeAmerican Community Schools, Athens, GreeceHonors and Awards1996 NHLBI Director’s Bonus Award1996 NIH Director’s Award1997 NIH Merit Award1998 Grand Heart Award-American Heart Association1999 NHLBI Special Act Award2000 NHLBI Special Act Award2000 NIH Merit Award2001 NHLBI Special Act Award2002 NHLBI Special Act Award2003 NHLBI Special Act Award2004 NHLBI Special Act Award2

2005 NHLBI Special Act Award2005 NIH Merit Award2006 NIH Merit Award2006 NIH Director’s Award2010 NIH Merit Award (4)2012 NHLBI Merit Award (3)Professional OrganizationsThe American Physiological SocietyAmerican Heart Association (Fellow)The American Society of Gene and Cell TherapyNorth American Vascular Biology OrganizationCommittees/Working Groups1993-1996 NHLBI Minority Supplement Review Committee1994-1995 NHLBI Human Resource Management Framework Committee1994-present NHLBI Molecular Genetics Group1995-2000 National Gene Vector Laboratories Steering Committee1997 NHLBI Redesign of TABS and PC Budget Committee1997 NCRR Strategic Planning Forum1997 NCRR Primate Committee1998-2001 NIH Staff Training in Extramural Programs Committee1998 NHLBI/IRTP Training Team Committee2000-2001 NIH Ad Hoc Gene Transfer Data and Safety Assessment Working Group2000-present NHLBI Gene Therapy Group (Chair)2000 NHLBI Retreat Planning Committee2000-2004 NHLBI Intramural Scientific Review Committee2000-2001 NIH Genetic Modification Clinical Research Information System DatabaseSteering Committee2001 NHLBI SCOR Program Committee2001 NIH Cardiovascular Sciences Steering Committee2001-present NHLBI Clinical Studies Coordinating Committee2001-2007 National Gene Vector Laboratories Steering Committee2002-2004 NHLBI Title 42 Review Committee2002-2003 NHLBI C Reactive Protein Committee2002-2005 NHLBI Antimicrobial Strategies and Cardiothoracic Surgery Committee2002-2004 NHLBI Type I Diabetes and Cardiovascular Complications Committee2003-present NHLBI Cell-Based Therapies Committee2003-2004 NHLBI Corporate Entity Committee2004 DHVD Retreat Planning Committee (Chair)2004-2005 Trans-NIH RNAi Working Group2005 NCRR Review Panel Member for National Gene Vector Laboratories2004-2010 Cardiovascular Gene Therapy Scientific Committee, American Society ofGene Therapy2004-2006 DHVD DEAS Implementation Group (Chair)3

2005-2009 NIH DEAS Advisory Committee2005-present NIH Gene Therapy Extramural Committee (Chair)2005-2007 Public Education Committee, American Society of Gene Therapy2006-2008 Trans-NIH RCDC Disease Fingerprinting Committee2007-2008 Roadmap 1.5 Regenerative Medicine Coordinating Committee2008 Trans-NIH Rare Diseases Working Group2009 CSR IRG Chief Search Committee2009 DCVS Workshop/Working Group Committee (Chair)2010 FDA/NIH Stem Cell Workshop Planning Group2010 CSR IRG Chief Search Committee2010-2011 NHLBI Type 5 Committee2011-present NIH High Risk/High Reward Committee2011-present NHLBI Topic Review Advisory Committee2011-2013 ASGCT Education Committee (co-chair)Liaisons2000-present NIH Recombinant DNA Advisory Committee2000-2004 Atherosclerosis, Thrombosis and Vascular Biology Council, AHA2000-2004 North America Vascular Biology Organization2000-present American Society of Gene Therapy2000-2002 Lifeline Foundation2000-2002 Cardiovascular and Interventional Radiology Research and EducationFoundation2003-2006 Atherosclerotic Peripheral Vascular Disease Interdisciplinary WorkingGroup/AHA2008-2009 NHLBI Computer Encryption CommitteeMeetings OrganizedUSA/Italy Genetic and Pharmacological Approaches in Vascular Biology Symposium (December1999)USA/Russia Cardiovascular Diseases Symposium (September 2001)Antimicrobial Strategies and Cardiothoracic Surgery Working Group (April 2002)Lp(a) and Cardiovascular Disease: Recent Advances and Future Directions (October 2002)Workshop on Cardiovascular Complications of Type 1 Diabetes: Identifying New Opportunitiesfor Prevention and Treatment (April 2003)CRP Pilot Feasibility Study Planning Working Group (June 2003)SCCOR in Vascular Diseases Working Group (December 2003)Vascular Medicine Training Program (March 2004)4

Gene Therapy Working Group (June 2005)USA/France Angiogenesis Symposium (June 2006)ASGCT Clinical Trials Workshop (May 2010)8 th Biomarkers and Surrogate Endpoints Symposium (September 2010)9 th Biomarkers: Emerging Biomarkers, Emerging Challenges (September 2011)ASGCT/NIH Gene Therapy Symposium (September 2011)ASGCT Educational Symposium (May 2012)ASGCT Cardiovascular Symposium (May 2012)ASGCT NIH Training Symposium (May 2013)ASGCT Hemoglobinopathies Symposium (May 2013)Programs DevelopedNHLBI Programs of Excellence in Molecular Biology (1990-2000): this program fostered theuse of molecular biology techniques in important research areas of interest to the Institute andtrained investigators in state of the art molecular biology techniques.Homocysteinemia and Atherosclerosis (1997-2001): this program promoted research into theprecise mechanisms by which homocysteine induces arterial occlusive disease and investigatedthe role of hyperhomocysteinemia in the development of atherosclerotic lesions.NHLBI Programs of Excellence in Gene Therapy (2000-2005): this program facilitated thetranslation of basic gene therapy studies into clinical applications and provided unique ongoingresources and education programs to NHLBI investigators.Role of Infectious Agents in Vascular Diseases (2001-2006): this program encouraged thecareful design of in vitro and in vivo studies that delineated the specific cellular and molecularmechanisms by which infectious agents contribute to atherogenesis.Fetal Non Human Primates Gene Transfer Center (2001-2012): this center provides uniqueexpertise, services, and resources to NHLBI-funded investigators who wish to evaluate viral andnon-viral gene transfer strategies in monkeys.Research Career Development Programs in Vascular Medicine (2005-2012): this programpromotes comprehensive clinical research training for physicians wanting to specialize inVascular Medicine.5

New Approaches to Non-Viral Systems for Gene Transfer Applications for Heart, Lung,and Blood Diseases (2006-2009): this program stimulates research towards the developmentof new and efficient non-viral vectors that scientists may use in gene therapy clinical trials.Small Business Innovation Research to Improve the Chemistry and Targeted Delivery ofRNAi Molecules (2006-2010): this program supports innovative research in the field of RNAisynthesis and delivery to defined target sites.Biology of RNA Interference: Stability, Delivery and Processing by Tissues (2006-2010):this program stimulates research towards the understanding of uptake and processing of RNAi.NHLBI Gene Therapy Resource Program (2007-2012; renewal 2012-2017): this programprovides resources in areas such as the production of preclinical and certified GMP (goodmanufacturing practices)-grade vectors and the conduct of pharmacology/toxicology studies. Italso includes resources for regulatory processes to initiate clinical trials.Cardiovascular Cell Therapy Research Network (2007-2012; renewal 2012-2019): thisprogram accelerates research in cell-based strategies in the diagnosis and management ofcardiovascular disease.Progenitor Cell Consortium (2010-2017): this program seeks to develop a betterunderstanding of stem and progenitor cell biology and their use.Science Moving Towards Translation and Therapy (SMARTT) (2010-2015): this programseeks to help translate basic discoveries into successful treatments for heart, lung and blooddiseases.National Gene Vector Biorepository (NGVB) (2012): In 2008, the NIH through the NationalCenter for Research Resources (NCRR) established the NGVB and Coordinating Center as aresource for NIH-funded investigators in gene therapy research to store, retrieve test, and studyvectors, tissues and other products related to gene therapy. The NGVB also developed apharmacology/toxicology database to share with the extramural community. In 2012, the NHLBIassumed the responsibility of the NGVB.Invited Presentations1990 “Cholesterol Metabolism in Human Monocyte-Derived Macrophages”Baltimore- Washington Lipid SocietyWashington D.C.1990 “Cholesterol Metabolism in Human Monocyte-Derived Macrophages”MidAtlantic Lipid SocietyAtlantic City, New Jersey1991 “Cholesterol Metabolism in Human Monocyte-Derived Macrophages’Merck, Sharp and DohmeWest Point, Pennsylvania6

1994 “Grant Writing Strategies”Women in Arteriosclerosis Luncheon Workshop, AHADallas, Texas1996 “The Potential and Challenges of Gene Therapy”Research Initiatives in Vascular DiseaseBethesda, Maryland1996 “Gene Therapy for Familial Hypercholesterolemia”DHVD Journal ClubBethesda, Maryland1996 “Overview of NHLBI Resources for Gene Therapy”Gene Therapy Conference, FDA and NCIBethesda, Maryland1996 “Highlights of the POEMBs”DHVD Seminar SeriesBethesda, Maryland1996 “The Programs of Excellence in Molecular Biology”National Heart, Lung, and Blood Advisory CouncilBethesda, Maryland1998 “Navigating NIH: What=s New in Review and Program”North American Vascular Biology MeetingSan Francisco, California1998 “Grant Applications: What’s New in Review and Program”Experimental Biology SocietySan Francisco, California1998 “Overview of the Programs of Excellence in Molecular Biology”13th International Interdisciplinary Conference on Hypertension in BlacksCharleston, South Carolina1999 “NHLBI Programs in Gene Therapy”The American Society of Gene TherapyWashington D.C.1999 “Highlights of NHLBI Programs in Genetics and Gene Therapy”US-Italy Symposium on Genetic and Pharmacological Approaches inVascular BiologyMilan, Italy2000 “Joint Lifeline Foundation/NHLBI K08 Awards”The Society for Vascular Surgery7

Toronto, Canada2000 “NHLBI Gene Therapy Oversight”National Heart, Lung, and Blood Advisory CouncilBethesda, Maryland2001 “NHLBI Gene Therapy Monitoring”NHLBI DEA ForumBethesda, Maryland2001 “NIH and the Vascular Surgeon”Research Initiatives MeetingBethesda, Maryland2001 “Initiative Mechanisms”Arteriosclerosis, Thrombosis, and Vascular Biology Annual MeetingCrystal City, Virginia2001 “Data and Safety Monitoring”American Society of Gene TherapySeattle, Washington2001 “Clinical Protocol Development”American Society of Gene TherapySeattle, Washington2001 “Programs of Excellence in Gene Therapy”NIH Recombinant Advisory CommitteeBethesda, Maryland2002 “NIH Guidelines and Programs in Gene Therapy”Human Gene Therapy Institute Seminars at PennPhiladelphia, Philadelphia2002 “NIH Programs in Gene Therapy”Cardiovascular Cell and Gene Therapy ConferenceBoston, Massachusetts2002 “Role of NIH Program Staff”American Society of Gene TherapyBoston, Massachusetts2003 “Cardiovascular Health and Diseases Panel”Fourth Annual Public Interest Organization MeetingBethesda, Maryland2003 “Programs of Excellence in Gene Therapy’American Society of Gene Therapy8

Washington DC2004 “New SCCOR Program Update’NHLBI Hypertension Grantees’ MeetingBethesda, Maryland2004 “Patching your genes: converting gene therapy’s promise to practice”NHLBI Annual Public Interest Organization MeetingBethesda, Maryland2004 “Update on NHLBI Inititatives and the NIH Roadmap’Research in Initiatives Conference in Vascular DiseasesBethesda, Maryland2004 “NIH/NHLBI Policies and Regulations for Gene Therapy Studies”Cardiovascular Cell and Gene Therapy ConferenceBoston, Massachusetts2004 “NHLBI Gene Therapy Resources”American Society of Gene TherapyMinneapolis, Minnesota2004 “Programs of Excellence in Gene Therapy”American Society of Gene TherapyMinneapolis, Minnesota2004 “Role of the NIH Program Officer”American Society of Gene TherapyMinneapolis, Minnesota2004 “Panel Discussant on Vector Types for Cystic Fibrosis”Cystic Fibrosis Gene Therapy MeetingBethesda, Maryland2004 “Panel Discussant on Cell and Gene Therapies”FDA Workshop on Cellular, Tissue and Gene TherapiesGaithersburg, Maryland2004 “NHLBI Resources and Initiatives”Gene Therapy Symposium for Heart, Lung and Blood DiseasesSonoma, California2005 “Training and Career Development”American Society of Gene TherapySt. Louis, Missouri2005 “NHLBI Resources in Support of Gene Therapy”Gene Therapy Symposium for Heart, Lung and Blood DiseasesSonoma, California9

2006 “NHLBI/NIH Funding Mechanisms”2 nd International Conference on Cell Therapy for CVDNew York, New York2006 “Challenges Facing Gene Therapy in Heart, Lung, and Blood Diseases”Cell and Gene Therapy Forum 2006Baltimore, Maryland2006 “NHLBI Research Training and Early Career Development Opportunities”Keystone SymposiumSanta Fe, New Mexico2006 “NHLBI Gene Therapy Programs”Cardiovascular Cell and Gene Therapy Conference IIIBoston, Massachusetts2006 “NHLBI/NIH Resources for Gene and Cell Based Therapies”American Society of Gene TherapyBaltimore, Maryland2006 “NHLBI Update“NHLBI Minority Investigators Meeting, American Heart AssociationChicago, Illinois2007 “NHLBI Update and Reorganization“Heart Failure SocietyBethesda, Maryland2007 “NHLBI/NIH Resources for Gene- and Cell-Based Therapies“7 th World Congress on Trauma, Shock, Inflammation and SepsisMunich, Germany2007 “NHLBI Strategic Plan and Funding Updates “Research Initiatives in Vascular Disease ConferenceWashington D.C.2007 “NHLBI Gene Therapy Resource Program”NIH Recombinant DNA Advisory CommitteeBethesda, Maryland2007 “NHLBI Cardiovascular Cell-Based Network”Cardiovascular Regenerative Medicine SymposiumBethesda, Maryland2007 “NHLBI Cardiovascular Cell-Based Network”American Heart AssociationOrlando, Florida10

2008 “NIH Perspective: NHLBI Resources for gene and cell-based therapies”Phacilitate ForumWashington DC2008 “Gene and Cell-Based Programs at the NHLBI”4 th Cardiovascular Cell and Gene Therapy ConferenceNew York, New York2009 “NHLBI Cell-Based Programs”United Kingdom’s Engineering and Physical Sciences Research CouncilBethesda, Maryland2009 “Bench to Bedside: NHLBI Efforts in Cell Therapy”American Heart AssociationOrlando, Florida2009 “Bench to Bedside: NHLBI Efforts in Gene and Cell Therapies”NHLBI SymposiumBethesda, Maryland2010 “Challenges in Cell Delivery to the Heart”Phacilitate ForumWashington DC2010 “What Vector and Cell Resources are Available to Investigators?”Gene and Cell Therapy Clinical Trials Training CourseWashington DC2010 “NHLBI Gene Therapy Resources”American Society of Gene and Cell TherapyWashington DC2010 “NHLBI Resources”8 th Biomarkers and Surrogate Endpoints SymposiumBethesda, MD2011 “NHLBI Gene Therapy Resources”American Society of Gene and Cell TherapySeattle, WA2011 “Autologous Stem Cells for Cardiovascular Diseases”Briefing for Senator Harkin’s StaffCapitol Hill, Washington DC2011 “NHLBI Gene and Cell Therapy Resources”ASGCT/NIH SymposiumBethesda, MD11

2011 “Bench to Bedside: NHLBI’s Efforts in Gene and Cell Therapies”Opening Ceremony Speaker9th International Congress on Coronary Artery Disease: From Preventionto InterventionVenice, Italy2011 “Overview of NHLBI Gene Therapy Resources”National Center for Research ResourcesBethesda, MD2012 “Perspective of the NHLBI”American College of CardiologyChicago,IL2012 “Innovations from the US National Institutes of Health”10 th Annual Cardiovascular Biomarkers SymposiumDublin, Ireland2012 “Gene Therapy Resources”American Society of Gene and Cell TherapyPhiladelphia, PA2012 “The NHLBI Gene Therapy Resource Program”Gene Transfer Orphan Disease WorkshopBethesda, MD2012 “NHLBI Resources to Advance Translational Research”NHLBI Mid-Atlantic Innovation ConferenceRockville, MD2012 “The Federal’s Commitment to Funding High Potential Stem CellResearch”8 th World Stem Cell SummitWest Palm Beach, FLPublications1. Reeves, W., Cunningham, D., Schwiter, J., Abt, A., Skarlatos, S., Wood, M., andWhitesell, L.: Myocardial hydroxyproline reduced by early administration ofmethylprednisone or ibuprofen to rabbits with radiation-induced heart disease.Circulation 65:924-927, 1982.2. Skarlatos, S.I.: Effects of shear stress on bovine endothelial cells, in vitro, with relation tothe pathogenesis of atherosclerosis. Ph.D Thesis. The Pennsylvania State University,University Park, PA, 1985.3. Skarlatos, S.I. and Hollis, T.M.: Cultured bovine aortic endothelial cells show increase in12

histamine metabolism when exposed to oscillatory shear stress. Atherosclerosis 64:55-61, 1987.4. Chao, F.-F., Amende, L.M., Blanchette-Mackie, J., Skarlatos, S.I., Gamble, W., Resau,J.H., Mergner, W.T. and Kruth, H.S.: Unesterified cholesterol-rich lipid particles inatherosclerotic lesions of human and rabbit aortas. Amer.J.Path. 131:73-83, 1988.5. Skarlatos, S.I., Amende, L., Chao, F.-F, Blanchette-Mackie, J., Gamble, W. and Kruth,H.S.: Biochemical characterization of isolated cholesterol-phospholipid particlescontinuously released from rat and human platelets after activation. Lab. Invest. 59:344-352, 1988.6. Amende, L.M., Skarlatos, S.I., Kruth, H.S. and Blanchette-Mackie, J.: Structure ofcholesterol-containing particles released from activated human platelets. J. Vasc. Med.Biol. 1:129-136, 1989.7. Chao, F.-F., Blanchette-Mackie, E.J., Chen, Y.-J., Dickens, B.F., Berlin, E., Amende,L.M., Skarlatos, S.I., Gamble, W., Resau, J.H., Mergner, W.T. and Kruth, H.S.:Characterization of two unique cholesterol-rich lipid particles isolated from humanatherosclerotic lesions. Amer. J. Path., 136:169-179, 1990.8. Beg, O.U., Meng, M.S., Skarlatos, S.I., Previato, L., Brunzell, J.D., Brewer, H.B. Jr., andFojo, S.S.: Lipoprotein lipase Bethesda: A single amino acid substitution (Ala-176 to Thr)leads to abnormal heparin binding and loss of enzymic activity. Proc. Natl. Acad. Sci.U.S.A. 87:3474-3478, 1990.9. Dichek, H.L., Fojo, S.S., Beg, O.U., Skarlatos, S.I., Brunzell, J.D., Cutler, G.B., Jr., andBrewer, H.B. Jr.: Identification of two separate allelic mutations in the lipoprotein lipasegene of a patient with the familial hyperchylomicronemia syndrome. J. Biol. Chem.266:473-477, 1991.10. Chao, F.-F., Blanchette-Mackie, E.J., Tertov, V.V., Skarlatos, S.I., Chen, Y.-J. and Kruth,H.S.: Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein toa liposome. J. Biol. Chem. 267:4992-4998, 1992.11. Skarlatos, S.I., Rao, R., and Kruth, H.S.: Accelerated development of human monocytemacrophagescultured on Plastek C tissue culture dishes. J. Tissue CultureMethods,14:113-118, 1992.12. Lesnik, P., Rouis, M., Skarlatos, S., Kruth, H.S. and Chapman, M.J.: Uptake ofexogenous free cholesterol induces upregulation of tissue factor expression in humanmonocyte-derived macrophages. Proc. Natl. Acad. Sci. USA, 89:10370-10374. 1992.13. Lohse, P., Brewer, H.B.III, Meng, M.S., Skarlatos, S.I., LaRosa, J.C. and Brewer, H.B.Jr.: Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to apremature stop codon in the apolipoprotein E gene. J.Lipid Res., 33:1583-1590, 1992.14. Skarlatos, S.I., Dichek, H.L., Fojo, S.S., Brewer, H.B. and Kruth, H.S.: Absence oftriglyceride accumulation in lipoprotein lipase-deficient human monocyte-macrophagesincubated with human very low density lipoprotein. J. Clin. Endocr. Met., 76:793-796,13

1993.15. Skarlatos, S.I., Rouis, M., Chapman, M.J., and Kruth, H.S.: Heterogeneity of cellularcholesteryl ester accumulation by human monocyte-derived macrophages.Atherosclerosis, 99:229-240, 1993.16. Skarlatos, S.I., Rao, R., Dickens, B.F., and Kruth, H.S.: Phospholipid changes in dyingplatelets. Virchows Archives, 64:241-245, 1993.17. Ershow, A.G. and Skarlatos, S.I.: Diet and risk factors for coronary heart disease: anupdate. Contemporary Nutrition, Vol.18, no.1, 1993.18. Kruth, H.S., Skarlatos, S.I., Gaynor, P.M., and Gamble, W.: Production of cholesterolenrichednascent HDL by human monocyte-derived macrophages is a mechanism thatcontributes to macrophage cholesterol efflux. J. Biol. Chem., 269:24511-24518, 1994.19. Skarlatos, S.I., Duverger, N., Rader, D. and Kruth, H.S.: Cholesterol Efflux from HumanMonocyte-Derived Macrophages in the presence of Lp A-I:A-II. Biochimica et BiophysicaActa, 1270:19-25, 1995.20. Kruth, H.S., Skarlatos, S.I., Lilly, K., Chang, J., and Ifrim, I.: Sequestration of cholesterolcrystals by human monocyte-derived macrophages. J. Cell Biology, 129:133-145, 1995.21. Gaynor, P., Zang, W.-Y., Weiss, J.S., Skarlatos, S.I., Rodrigues, M.M. and Kruth, H.S. :Accumulation of HDL Apolipoproteins Accompanies Abnormal Cholesterol Accumulationin Schnyder's Corneal Dystrophy. Arterioscler. Thromb. Vasc. Biol., 16:992-999, 199622. Libby, P., Egan, D., and Skarlatos, S. : Roles of Infectious Agents in Atherosclerosis andRestenosis. An Assessment of the Evidence and Need of Future Research. Circulation,96:4095-4103, 199723. Kruth, H., Zhang, W.-Y., Skarlatos, S., and Chao, F.-F.: Apolipoprotein B stimulatesformation of monocyte-macrophage surface-connected compartments and mediatesuptake of LDL-derived liposomes into these compartments. J.Biol. Chem, 274:495-7500,199924. Byrne, G., Skarlatos, S., Grunfeld, C., Kalayoglu, M., Libby, P., Saikku, P., Summersgill,J., and Wyrick, P.: Collaborative Multidisciplinary Workshop Report: Interface of LipidMetabolism, Atherosclerosis, and Chlamydia Infection. J.Infect.Dis., 181 (Suppl. 3):S490-1, 200025. Skarlatos, S, Velletri, P., and Morris, M., Editors for Annals of The New York Academy ofSciences: New Vistas in Therapeutics: From Drug Design to Gene Therapy. Vol. 953,200126. Skarlatos, S.: Homocysteine: An Emerging Risk Factor. Ethnicity and Disease, 12 (1):S1-38, 200214

27. Marcovina, S.M., Koschinsky, M.L., Albers, J.J., and Skarlatos, S.: Lipoprotein (a) andCardiovascular Disease: Recent Advances and Future Directions. Clinical Chemistry, 49(11): 1785-1796, 200328. Lowy, F, Waldhausen, J., Miller, M., Sopko, G., Rosenberg, Y., and Skarlatos, S.: Reportof the NHLBI-NIAID Working Group on Antimicrobial Strategies and CardiothoracicSurgery. American Heart Journal, 147; 575-581, 200429. Libby, P., Nathan, D., Abraham, K., Brunzell, J., Fradkin, J., Haffner S., Hsueh, W.,Rewers, M., Roberts, T., Savage, P., Skarlatos, S., Wassef, M., and Rabadan-Diehl, C:Report of the NHLBI-NIDDK Working Group on Cardiovascular Complications of Type 1Diabetes Mellitus. Circulation, 111; 3489-3493, 200530. Woo, S. L., Skarlatos, S.I., Joyce, M.M., Croxton, T.L., and Qasba, P.: Critical Resourcesfor Gene Therapy in Heart, Lung and Blood Diseases Working Group. MolecularTherapy, Vol. 13, No.4: 641-643, 200631. Skarlatos, S.I.: NHLBI Resources and Programs for Gene Therapy in Heart, Lung andBlood Diseases. Circ Res, 100:1667-1669, 200732. Skarlatos, S.I.: New Programs for Gene- and Cell-Based Therapies at NHLBI. ClinicalPharmacology and Therapeutics, 82 (3):334-336, 200733. Traverse, J.H., Henry, T.D., Vaughn, D.E., Ellis, S.G., Pepine, C.J., Willerson, J.T., Zhao,D.X.M., Penn, M.S., Byrne, B.J., Perin, E.C., Gee, A.P., Hatzopoulos, A.K., McKenna,D.H., Piller, L.B., Forder, J.R., Taylor, D.A., Cogle, C.R., Olson, R.E., Jorgenson, B.C.,Sayre, S.l., Vojvodic, R.W., Gordon, D.J., Skarlatos, S.I., Moye, L.A., and Simari, R.D.:Rational and Design for TIME: A Phase-II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Timing of Administration of Bonemarrow Mononuclear Cells Following Acute Myocardial Infarction. American HeartJournal, 158:356-63, 200934. Lauer, M.S., Skarlatos, S.I., and Bild, D.E.: The Extramural Division of CardiovascularSciences of NHLBI. J Am Coll Cardiol., 54 (3):265-268, 200935. Simari, R.D., Moye, L.A., Skarlatos, S.I., Ellis, S.G., Zhao, D.X.M., Willerson, J.T., Henry,T.D., and Pepine, C.J.: Development of a Network to Test Strategies in CardiovascularDelivery: the NHLBI Sponsored-Cardiovascular Cell Therapy Research Network. J.Cardiovascular Translational Research, 3:30-36, 201036. Lauer, M., Skarlatos, S.I.: Translational Research for Cardiovascular Diseases at theNHLBI: Moving from Bench to Bedside and From Bedside to Community. Circulation,21(7):929-33, 201037. Traverse, J.H., Henry, T.D., Vaughn, D.E., Ellis, S.G., Pepine, C.J., Willerson, J.T.,Zhao, D.X.M., Simpson, L., Penn, M.S., Byrne, B.J., Perin, C., Gee, A., Hatzopoulos,A.K., McKenna, D.H., Forder, J.R., Taylor, D.A., Cogle, C.R., Baraniuk, S., Olson, R.,Jorgenson, B.C., Sayre, S.L., Vojvodic, R. W., Gordon, D.J., Skarlatos, S.I., Moyé, L.A.,15

and Simari, R.D.: LateTIME: a Phase-II Randomized, Double-Blind, Placebo-Controlled,Pilot Trial Evaluating the Safety and Effect of Administration of Bone MarrowMononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction. Texas Heart InstituteJournal, 37(4):412-420, 201038. Willerson, J.T., Perin, E.C., Ellis, S.G., Pepine, C.J., Henry, T.D., Zhao, D.X.M., Lai, D.,Penn, M.S., Byrne, B.J., Silva, G., Gee, A., Traverse, J.H., Hatzopoulos, A.K., Forder,J.R., Martin, D., Kronenberg, M., Taylor, D.A., Cogle, C.R., Baraniuk, S., Westbrook, L.,Sayre, S.L., Vojvodic, R. W., Gordon, D.J., Skarlatos, S.I., Moyé, L.A., and Simari, R.D.:Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells for Patients withChronic Ischemic Heart Disease and Left Ventricular Dysfunction (First MononuclearCells Injected in the US[FOCUS]): Rationale and Design. American Heart Journal, 160(2): 215-223, 201039. Gee, A.P., Richman, S., Durett, A., McKenna, D., Traverse, J., Henry, T., Fisk, D.,Pepine, C., Bloom, J., Willerson, J., Prater, K., Zhao, D., Koc, J.R., Ellis, S., Taylor,D.,Cogle, C., Moye, L., Simari, R. and Skarlatos, S. : Multicenter Cell Processing forCardiovascular Regenerative Medicine Applications: The Cardiovascular Cell TherapyResearch Network (CCTRN) Experience. Cytotherapy, 12 (5):684-91, 201040. Lathrop, D.A, and Skarlatos, S.I.: Current NHLBI Perspectives on Translational HeartFailure Research. J Mol Cell Cardiol, doi:10.1016/j.ymcc.2010.09.026, 201041. Moye, L.A, Sayre, S., Westbrook, L., Jorgenson, B., Handberg, E., Anwaruddin, S.,Wagner, K., Skarlatos,S.I.: Oversight and Management of a Cell Therapy Clinical TrialNetwork: Experience and Lessons Learned. Contemporary Clinical Trials, 32:614-619,201142. Richman, S., Gee, A.P., McKenna, D. Traverse, J., Henry, T., Fisk, D., Pepine, C.,Bloom, J., Willerson, J., Prater, K., Zhao, D., Reese Koc, J., Ellis, S., Taylor, D., Cogle,C., Moye, L., Simari, R., and Skarlatos, S.: Factors affecting the Turnaround Time forManufacturing, Testing and Release of Cellular Therapy Products prepared at MultipleSites in support of Multicenter Cardiovascular Regenerative Medicine Protocols – aCardiovascular Cell Therapy Research Network (CCTRN) Study. Transfusion, Feb 2011,on line43. Traverse, J.H., Henry, T.D., Ellis, S.G., Pepine, C.J., Willerson, J.T., Zhao, D.X.M.,Forder, J.R., Byrne, B.J., Hatzopoulos, A.K., Penn, M.S., Perin, E.C., Baran, K.W.,Chambers, J., Lambert, C., Raveedran, G., Simon, D.I., Vaughan, D.E., Simpson, L.M.,Gee, A.P., Taylor, D.A., Cogle, C.R., Thomas, J.D., Silva, G.V., Jorgenson, B.C., Olson,R.E., Bowman, S., Francescon, J., Geither, C., Handeberg, E., Smith, D.X., Baraniuk,S., Piller, L.B., Loghin, C., Aguilar, D., Richman, S., Zierold, C., Bettencourt, J., Sayre, S.,Vojvodic, R. W., Skarlatos, S.I., Gordon, D.J., Ebert, R., Kwak, M., Moyé, L.A., andSimari, R.D. for the Cardiovascular Cell Therapy Research Network (CCTRN): Effect ofIntracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 WeeksFollowing Acute Myocardial Infarction on Left Ventricular Function. The LateTIMERandomized Trial. JAMA, 306:2110-2119, 201116

44. Buxton, D., and Skarlatos, S.I.: Support for Cardiovascular Cell Therapy Research at theNational Heart, Lung and Blood Institute. Circulation Research, 110: 1549-1555, 2012.45. Perin, E.C., Willerson, J.T., Pepine, C.J., Henry, T.D., Ellis, S.G., Zhao, D.X.M., Lai, D.,Thomas, J.D., Kronenberg, M.W., Martin, A.D., Guilherme, V.S., Byrne, B.J., Traverse,J.H., Penn, M.S., Anwaruddin, S., Hatzopoulos, A.K., Gee, A.P., Taylor, D.A., Cogle,C.R., Smith, D.X., Westbrook, L., Handberg, E., Olson, R.E., Geither, C., Bowman, S.,Francescon, J., Baraniuk, S., Piller, L.B., Simpson, L.M., Longhin, C., Aguilar, D.,Richman, S., Zierold, C., Bettencourt, J., Sayre, S., Vojvodic, R. W., Skarlatos, S.I.,Gordon, D.J., Ebert, R.F., Kwak, M., Moyé, L.A., and Simari, R.D. for the CardiovascularCell Therapy Research Network (CCTRN): Effect of Transendocardial Delivery ofAutologous Bone Marrow Mononuclear Cells on Functional Capacity, Left VentricularFunction, and Perfusion in Chronic Ischemic Heart Failure: The FOCUS-CCTRN Trial.JAMA, 307:1717-1726, 201246. Richman, S., Gee, A.P., McKenna, D.H., Traverse, J.H., Henry, T.D., Fisk, D., Pepine,C.J., Bloom, J., Willerson, J.T., Prater, K., Zhao, D., Koc, J.R., Anwarrudin, S., Taylor,D.A, Cogle, C.R., Moye, L.A., Simari,R.D., and Skarlatos, S.: Factors affecting theturnaround time for manufacturing, testing, and release of cellular therapy productsprepared at multiple sites in support of a multicenter cardiovascular regenerativemedicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.Transfusion, 52:2225-2233, 201247. Tarantal, A. and Skarlatos, S.I.: Center for Fetal Monkey Gene Transfer for Heart, Lung,and Blood Diseases: An NHLBI Resource for the Gene Therapy Community. HumanGene Therapy, 23:1130-1135, 201248. O’Reilly, M, Kohn, D., Bartlett, J., Benson, J., Brooks, P., Byrne, B., Cammozi, C.,Cornetta, K., Crystal, R., Fong, Y., Gargiulo, L., High, K., Jacobson, S., Jambou, R.,Montgomery, M., Rosenthal, E., Samulsky, R.J., Skarlatos, S., Sorrentino, B., Wilson, J.,Xie, Y., Corrigan-Curay, J.: Gene Therapy for Rare Diseases: Summary of a NationalInstitutes of Health Workshop, September 13, 2012. In preparation49. McDonald, C., et al: The NHLBI Gene Therapy Resource Program; the last 5 years. Inpreparation50. Galis, Z., Black, J., and Skarlatos, S.I: National Heart, Lung, and Blood Institute and theTranslation of Cardiovascular Discoveries into Therapeutic Approaches. January 2013.Submitted to Circ Research51. Skarlatos, S.I., et al: Type 5 progress reports. In preparation17